CA2948839A1 - Dosage of dasotraline and method for treatment of adhd - Google Patents

Dosage of dasotraline and method for treatment of adhd Download PDF

Info

Publication number
CA2948839A1
CA2948839A1 CA2948839A CA2948839A CA2948839A1 CA 2948839 A1 CA2948839 A1 CA 2948839A1 CA 2948839 A CA2948839 A CA 2948839A CA 2948839 A CA2948839 A CA 2948839A CA 2948839 A1 CA2948839 A1 CA 2948839A1
Authority
CA
Canada
Prior art keywords
dasotraline
adhd
treatment
methylphenidate
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2948839A
Other languages
English (en)
French (fr)
Inventor
Antony D. Loebel
Kenneth S. Koblan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CA2948839A1 publication Critical patent/CA2948839A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2948839A 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd Abandoned CA2948839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992619P 2014-05-13 2014-05-13
US61/992,619 2014-05-13
PCT/US2015/030357 WO2015175523A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Publications (1)

Publication Number Publication Date
CA2948839A1 true CA2948839A1 (en) 2015-11-19

Family

ID=54480549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948839A Abandoned CA2948839A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Country Status (10)

Country Link
US (1) US10076503B2 (enExample)
EP (1) EP3143000A4 (enExample)
JP (1) JP2017515849A (enExample)
KR (1) KR20170005088A (enExample)
CN (1) CN106660937A (enExample)
AU (1) AU2015259346A1 (enExample)
CA (1) CA2948839A1 (enExample)
IL (1) IL248847A0 (enExample)
MX (1) MX2016014768A (enExample)
WO (1) WO2015175523A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
KR101067045B1 (ko) * 2002-09-16 2011-09-22 선오비온 파마슈티컬스 인코포레이티드 트랜스 ４－（３，４－디클로로페닐）－１，２，３，４－테트라하이드로－１－나프탈렌아민을 사용한 ｃｎｓ 장애의 치료
US8957114B2 (en) 2009-12-04 2015-02-17 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof

Also Published As

Publication number Publication date
WO2015175523A1 (en) 2015-11-19
CN106660937A (zh) 2017-05-10
IL248847A0 (en) 2017-01-31
KR20170005088A (ko) 2017-01-11
AU2015259346A1 (en) 2016-12-08
EP3143000A1 (en) 2017-03-22
US20170266134A1 (en) 2017-09-21
MX2016014768A (es) 2017-03-06
EP3143000A4 (en) 2017-12-13
US10076503B2 (en) 2018-09-18
JP2017515849A (ja) 2017-06-15

Similar Documents

Publication Publication Date Title
JP6332651B2 (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
US20070117838A1 (en) Quinine dosage forms and methods of use thereof
JP2013505983A5 (enExample)
KR20170068480A (ko) 다발성 경화증의 치료를 위한 시포니모드 및 라퀴니모드를 포함하는 조합물
CN110167562A (zh) Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
AU2024266870A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
US20170266133A1 (en) Methods and compositions of dasotraline for treatment of adhd
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
US10076503B2 (en) Dosage of dasotraline and method for treatment of ADHD
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
US20240342160A1 (en) Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
Schmidt et al. P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia
JP2011522051A (ja) 注意欠陥／多動性障害のためのｓｏｆｉｎｉｃｌｉｎｅ（ａｂｔ−８９４）
Willis et al. P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic
KR20220108123A (ko) 치매 환자의 행동 및 심리적 증상 치료

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123

FZDE Discontinued

Effective date: 20211123